Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2007.11.6053 on October 1 2007

Journal of Clinical Oncology, Vol 25, No 31 (November 1), 2007: pp. 4938-4945
© 2007 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmid, C.
Right arrow Articles by Rocha, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmid, C.
Right arrow Articles by Rocha, V.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party

Christoph Schmid, Myriam Labopin, Arnon Nagler, Martin Bornhäuser, Jürgen Finke, Athanasios Fassas, Liisa Volin, Günham Gürman, Johan Maertens, Pierre Bordigoni, Ernst Holler, Gerhard Ehninger, Emmanuelle Polge, Norbert-Claude Gorin, Hans-Jochem Kolb, Vanderson Rocha

From the Department of Medicine II, Klinikum Augsburg, Ludwig Maximilians University of Munich; Jose; Carrears Unit for Hematopoietic Transplantation, Department of Medicine III, Ludwig Maximilians University of Munich; Department of Hematology and Oncology, University of Dresden; Department of Medicine-Hematology, Oncology, University of Freiburg; Department of Hematology and Oncology, University Regensburg, Germany; Acute Leukemia Working Party-European Group of Blood and Marrow Transplantation; Hôpital Saint-Antoine AP-HP et Université Pierre et Marie Curie; Bone Marrow Transplant Unit, Hôpital Saint Louis, Université de Paris 7, Paris; Unité de transplantation médullaire, Hôpital d'enfants de Brabois-Médecine Infantile II, Vandoeuvre Les Nancy, France; Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Israel; George Papanicolaou General Hospital, Thessaloniki, Greece; Department of Medicine, Helsinki University Central Hospital, HUS Helsinki, Finland; Adult Stem Cell Transplantation Unit, Ankara University, Faculty of Medicine, Ankara, Turkey; and the Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium

Address reprint requests to Christoph Schmid, MD, Department of Medicine II, SCT Unit, Klinikum Augsburg, Ludwig-Maximilians-Universität München, PO Box 101920, 86009 Augsburg, Germany; e-mail: christoph.schmid{at}2med.zk.augsburg-med.de

Purpose To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).

Patients and Methods We retrospectively analyzed the data of 399 patients with AML in first hematological relapse after HSCT whose treatment did (n = 171) or did not (n = 228) include DLI. After correction for imbalances and established risk factors, the two groups were compared with respect to overall survival. Further, a detailed analysis of risk factors for survival among DLI recipients was performed.

Results Median follow-up was 27 and 40 months, respectively. Estimated survival at 2 years (± standard deviation) was 21% ± 3% for patients receiving DLI and 9% ± 2% for patients not receiving DLI. After adjustment for differences between the groups, better outcome was associated with age younger than 37 years (P = .008), relapse occurring more than 5 months after HSCT (P < .0001), and use of DLI (P = .04). Among DLI recipients, a lower tumor burden at relapse (< 35% of bone marrow blasts; P = .006), female sex (P = .02), favorable cytogenetics (P = .004), and remission at time of DLI (P < .0001) were predictive for survival in a multivariate analysis. Two-year survival was 56% ± 10%, if DLI was performed in remission or with favorable karyotype, and 15% ± 3% if DLI was given in aplasia or with active disease.

Conclusion Although further evidence for a graft-versus-leukemia effect by DLI is provided, our results confirm, that the clinical benefit is limited to a minority of patients. Strategies to reduce tumor burden before DLI, as well as alternative treatment options should be investigated in adults with relapsed AML after HSCT.

published online ahead of print at www.jco.org on October 1, 2007.

Presented in part at the meeting of the American Society of Hematology, San Diego, CA, December 4-7, 2004, and at the European Group for Blood and Marrow Transplantation, Prague, Czech Republic, March 20-23, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
B. R. Dey, T. R. Spitzer, and R. P. Hasserjian
Case 28-2009 -- A 68-Year-Old Man with Fatigue, Cough, and Peripheral-Blood Monocytosis
N. Engl. J. Med., September 10, 2009; 361(11): 1099 - 1106.
[Full Text] [PDF]


Home page
The OncologistHome page
E. L.J.M. Smits, Z. N. Berneman, and V. F.I. Van Tendeloo
Immunotherapy of Acute Myeloid Leukemia: Current Approaches
Oncologist, March 1, 2009; 14(3): 240 - 252.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H.-J. Kolb
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Blood, December 1, 2008; 112(12): 4371 - 4383.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Bornhauser, T. Illmer, U. Oelschlaegel, J. Schetelig, R. Ordemann, M. Schaich, M. Hanel, U. Schuler, C. Thiede, A. Kiani, et al.
Gemtuzumab Ozogamicin as Part of Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed Acute Myeloid Leukemia
Clin. Cancer Res., September 1, 2008; 14(17): 5585 - 5593.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
N. S. Majhail
Old and New Cancers after Hematopoietic-Cell Transplantation
Hematology, January 1, 2008; 2008(1): 142 - 149.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
S. Mackinnon
Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation
ASCO Educational Book, January 1, 2008; 2008(1): 334 - 337.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2007 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online